Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook

Paediatric Benznidazole Product Profile - Overview

An improved treatment option
  • Age-adapted, easy-to-use, affordable, and non-patented tablet, for the treatment of Chagas
  • disease in infants and young children under 2 years of age (20 kg body weight).
  • Contributes to improved dosing accuracy, safety, and adherence to treatment
  • Granted registration by Brazil’s National Health Surveillance Agency (ANVISA), with further endemic countries targeted for obtaining registration.

Main advantages of the Paediatric dosage form of Benznidazole
  • A single tablet allows coverage of a wide age range, up to 2 years old or body weight 20 kg
  • Child-adapted dose of 12.5 mg per tablet
  • Easily dispersible tablet to facilitate oral administration
  • No need for tablet fractionation (except for low-birth weight babies <2.5 kg: half a tablet)
  • Simple and reliable administration that does not require complex preparation and can therefore be administered at home, even during the long duration of treatment (twice daily for 60 days)

A collaborative partnership
Result of a three-year collaborative partnership, starting in 2008, between DNDi and the Pernambuco State Pharmaceutical Laboratory (Laboratório Farmacêutico do Estado de Pernambuco; LAFEPE) of Brazil. LAFEPE is the second largest public laboratory in Brazil and the only producer of benznidazole in the world.

Download Paediatric Benznidazole dossier (12/2011) [PDF]


Pediatric Benznidazole News
Watch PedBenz Videos

Portuguese 6'30''
Spanish      6'30''
English       6'30''

Granted registration in Brazil in late 2011!

Isabela Ribeiro, Poster
Population Pharmacokinetics of Benznidazole in Children......

Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site
is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License